Details:
The proceeds will advance company's lead drug, a potential first-in-class, disease-modifying recombinant protein designed to modulate the Wnt/β-catenin signalling pathway to regenerate pancreatic insulin-producing beta cells ,into clinical development in patients with T1D.
Lead Product(s): Undisclosed
Therapeutic Area: Endocrinology Product Name: Undislcosed
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim Venture Fund
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 10, 2023
Details:
AdipoPharma uses a novel approach to treating Type 2 diabetes. AdipoPharma’s drug, PATAS, treats insulin resistance, the root cause of Type 2 diabetes. PATAS has been designed while working on fat cells known as adipocytes.
Lead Product(s): PATAS
Therapeutic Area: Endocrinology Product Name: PATAS
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Newton Biocapital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series A Financing January 23, 2023
Details:
Amolyt Pharma is developing AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, as well as AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.
Lead Product(s): AZP-3601
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020